Angiotensin Converting Enzyme 2 News and Research

RSS

COVID-19 and blood group in aortic valve replacement

The COVID-19 pandemic has been found to cause disproportionate harm in patients with cardiovascular disease, especially among the elderly population, among other risk factors. However, a new study published on the preprint server medRxiv* in June 2020 is the first to report its clinical features in patients with aortic stenosis who have had a transcatheter aortic valve replacement (TAVR).

18 Jun 2020

COVID-19 could trigger diabetes in healthy people

The coronavirus disease (COVID-19) causes severe illness in people with underlying health conditions, such as heart disease, hypertension, lung illness, and diabetes. Now, scientists warn that viral infection may trigger the development of diabetes in healthy people.

18 Jun 2020

Scientists examine SARS-CoV-2 cell entry in different species

Researchers in China have demonstrated the ability of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to interact with the host cell receptors of multiple species of animals.

17 Jun 2020

An improved tetravalent antibody blocks SARS-CoV-2 infection

A new study published on the preprint server bioRxiv* in June 2020 shows the potential of a new fusion molecule called a biparatopic protein to inhibit viral interaction with the host cell ACE2 receptor. This could lead to therapeutic applications.

17 Jun 2020

SARS-CoV-2 mutated spike proteins show variations in cell entry

A new study by Japanese scientists published on the preprint server bioRxiv* in June 2020 shows that the D614g mutation in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein can enhance the infectivity of the virus while leaving it vulnerable to neutralization by antibodies.

17 Jun 2020

Novel ACE2-antibody fusion molecules show anti-SARS-CoV-2 activity

Now, in a new study published on the preprint server, bioRxiv researchers in the U.S. investigated a soluble version of ACE2 for SARS-CoV-2 viral neutralization activity.

17 Jun 2020

SARS-CoV-2 mutation reduces S1 shedding, increases infective potential

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the seventh coronavirus known to infect humans. SARS-CoV-2 emerged in the last month of 2019 in Wuhan, China, sparking off the ongoing COVID-19 pandemic. This virus enters the host cells through receptor binding and membrane fusion between the viral and host cell membrane.

16 Jun 2020

Inhaled steroids reduce ACE2 expression in COPD lungs

A new study by scientists at Imperial College London, University of Newcastle and Prokarium, and published on the preprint server bioRxiv* in June 2020 examines the role played by inhaled corticosteroids (ICS) in the risk of acquisition of COVID-19 infection by COPD patients.

15 Jun 2020

U.S. and European SARS CoV-2 mutation enhances transmission, increases infectivity

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that is causing the COVID-19 pandemic across the world has undergone a genetic mutation in the density of functional spikes on the virus, says a new study. This has led the virus to become highly infectious and easily transmissible between humans.

15 Jun 2020

Experimental drug to prevent deadly blood coagulation in patients with COVID-19

The British Heart Foundation is funding a trial for an experimental drug that could prevent the life-threatening blood clots that are seen in the lungs of the patients with COVID-19 or those infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The drug named TRV027 is said to normalize the hormonal imbalance that can be seen in patients developing COVID-19, experts said.

15 Jun 2020

An inverse relationship between smoking and COVID-19

Researchers at the University of Washington and Stanford University School of Medicine have reported a significant inverse relationship between current smoking and coronavirus disease 2019 (COVID-19) mortality rates across forty countries.

15 Jun 2020

Steroidal drugs subvert SARS-CoV-2 interaction with ACE2 receptors

A new study by Italian researchers and published online on the preprint server bioRxiv* in June 2020 reports the ability of several existing steroidal drugs to reduce the binding of the SARS-CoV-2 to the ACE2 receptor. This could help define newer strategies using viral entry blockers to reduce viral load.

14 Jun 2020

Remdesivir prevents replication of SARS-CoV-2 in human intestinal organoids

A new German study published on the preprint server bioRxiv* in June 2020 shows that the drug remdesivir can reduce the replication of SARS-CoV-2 in human intestinal organoids.

14 Jun 2020

An entire trimeric S-protein of SARS-CoV-2 is necessary for protective immune response

Researchers from Seattle Children's Research Institute and the University of Washington described a high-throughput and rapid technique to quantify circulating levels of functional antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), suggesting that the entire viral spike protein should be used to characterize the immune response. Their paper is currently available on the medRxiv* preprint server.

14 Jun 2020

Synthetic nanobodies potent neutralizers for SARS-CoV-2

Researchers at the Chinese Academy of Sciences report the generation of potent synthetic nanobodies that selectively and efficiently neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pseudovirus.

11 Jun 2020

Race-related differences in genetic determinants of COVID-19 severity

Researchers at the University of Iowa have identified differences in gene expression levels between African Americans and European Americans that may explain the disproportionately higher rates of coronavirus disease 2019 (COVID-19) cases and related deaths among African Americans.

11 Jun 2020

Scientists investigate immune responses to SARS-CoV-2 spike immunogens

The coronavirus pandemic is actively spreading across the globe, with millions of people infected. Amid the global health crisis, scientists race to develop an effective vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

10 Jun 2020